



## Arid Zone Journal of Basic and Applied Research

Faculty of Science, Kashim Ibrahim University  
Maiduguri, Nigeria

Journal homepage: <https://www.azjournalbar.com>



### Research Article

## Probiotics and Prebiotics in Gut Health Management

Victoria Auhoiza Joshua<sup>1</sup>, Joan Mayowa Oniemola<sup>1\*</sup>, Oluwatosin Cyril Obafemi<sup>2</sup> & Abdulrazaq Itopa Ahmad<sup>1</sup>

<sup>1</sup>Department of Science Laboratory Technology, School of Applied Sciences, Kogi State Polytechnic, Lokoja, Kogi State, Nigeria

<sup>2</sup>Department of Family Medicine, Federal Teaching Hospital, Lokoja, Kogi State, Nigeria

\*Corresponding author's Email: [joanmola01@gmail.com](mailto:joanmola01@gmail.com), [doi.org/10.55639/607.special.009](https://doi.org/10.55639/607.special.009)

#### ARTICLE INFO:

##### Keywords:

Gut microbiome,  
Strain-specific effects,  
Gastrointestinal disorders,  
Immune function.

#### ABSTRACT

The human gut microbiome plays a crucial role in maintaining overall health, influencing immune function, metabolism, and disease prevention. This review examines the current evidence supporting the use of probiotics and prebiotics in promoting gut health. Probiotics, defined as live microorganisms that confer health benefits when consumed in adequate amounts, and prebiotics, non-digestible food ingredients that selectively stimulate beneficial bacteria growth, have gained significant attention as therapeutic interventions. Recent clinical studies demonstrate their efficacy in treating gastrointestinal disorders, enhancing immune function, and supporting metabolic health. However, strain-specific effects, dosage considerations, and individual variability in response remain important factors for clinical application. This review synthesizes current research findings and provides evidence-based recommendations for the therapeutic use of probiotics and prebiotics in gut health management.

**Corresponding author** Joan Mayowa Oniemola, **Email:** [joanmola01@gmail.com](mailto:joanmola01@gmail.com)

Department of Science Laboratory Technology, School of Applied Sciences, Kogi State Polytechnic, Lokoja, Kogi State, Nigeria

#### INTRODUCTION

The human gastrointestinal tract harbors a complex ecosystem of microorganisms collectively known as the gut microbiome, comprising over 100 trillion bacterial cells representing more than 1,000 species (Hill *et al.*, 2014). This microbial community plays fundamental roles in digestion, immune system development, pathogen resistance, and metabolic

regulation. Disruption of the gut microbiome, termed dysbiosis, has been associated with numerous health conditions including inflammatory bowel disease, irritable bowel syndrome, allergies, and metabolic disorders (Rinninella *et al.*, 2019). The concept of modulating gut microbiota for health benefits has led to the development of probiotic and prebiotic interventions. Probiotics, which are

live microorganisms, have been demonstrated to enhance or replenish the gut microbiota, which have been connected to better health (Zhang *et al.*, 2024). Prebiotics, defined by Gibson *et al.* (2017) are substrates selectively utilized by host microorganisms conferring health benefits, which work synergistically with probiotics to enhance gut health.

The growing body of research supporting probiotics and prebiotics applications has prompted increased clinical interest and consumer adoption. However, the complexity of microbiome-host interactions necessitates a comprehensive understanding of mechanisms, efficacy, and safety considerations. This review aims to synthesize current evidence regarding probiotics and prebiotics for gut health, examining their therapeutic potential and clinical applications.

## 2.0 LITERATURE REVIEW

### 2.1 Mechanisms of Action

Probiotics exert their beneficial effects through multiple mechanisms. Primary mechanisms include competitive exclusion of pathogenic bacteria, production of antimicrobial substances such as bacteriocins and organic acids, enhancement of intestinal barrier function, and modulation of immune responses (Kerry *et al.*, 2018). *Lactobacillus* and *Bifidobacterium* species, the most commonly studied probiotics genera, demonstrate these properties through different pathways. *Lactobacillus* species produce lactic acid, creating an acidic environment that inhibits the growth of pathogenic bacteria while promoting the proliferation of beneficial bacteria. They also enhance tight junction proteins, strengthening intestinal barrier integrity (Martín *et al.*, 2013). Species excel in carbohydrate fermentation, producing short-chain fatty acids (SCFAs) that serve as energy sources for colonocytes and exhibit anti-inflammatory properties (O'Callaghan & van Sinderen, 2016).

Prebiotics which are indigestible fibres feed these good bacteria, thereby encouraging their growth and activity. When combined, probiotics and prebiotics form synbiotics, which work synergistically to enhance the gut microbiota balance, improving metabolic, immune, and hormonal health (Rodríguez-Herrera *et al.*, 2024).

### 2.2 Clinical Evidence for Application of Probiotics and Prebiotics

Substantial clinical evidence supports probiotics use in various gastrointestinal conditions. A systematic review by McFarland *et al.* (2016) demonstrated significant efficacy of specific probiotic strains in preventing antibiotic-associated diarrhea, with *Lactobacillus rhamnosus* GG and *Saccharomyces boulardii* showing the strongest evidence. For inflammatory bowel disease (IBD) management, probiotic interventions have shown mixed but promising results. In patients with ulcerative colitis, VSL#3, a multi-strain probiotic formulation, showed effectiveness in sustaining remission (Sood *et al.*, 2009). However, results vary significantly based on strain selection, dosage, and patient characteristics. Irritable bowel syndrome (IBS) represents another area where probiotics show therapeutic promise. A meta-analysis by Ford *et al.* (2018) revealed that certain probiotic strains, particularly *Bifidobacterium infantis* and *Lactobacillus plantarum*, significantly improved IBS symptoms compared to placebo.

Prebiotics research has focused primarily on fructooligosaccharides (FOS), galactooligosaccharides (GOS), and inulin. After surviving digestion in the upper gastrointestinal tract, these substances make their way to the colon, where they specifically encourage the growth of good bacteria. Clinical studies demonstrate that prebiotic supplementation increases *Bifidobacterium* and *Lactobacillus* populations while reducing potentially harmful bacteria such as *Clostridium* species (Gibson *et al.*, 2017). A randomized controlled trial by Vandeputte *et al.* (2017) showed that inulin supplementation significantly increased gut microbial diversity and SCFA production in healthy adults. These changes correlated with improved metabolic markers, including reduced inflammation and enhanced glucose tolerance.

### 2.3 Safety and Tolerability

Generally, probiotics demonstrate excellent safety profiles in healthy individuals and most patient populations. The most commonly reported adverse effects are mild gastrointestinal symptoms, including bloating and flatulence, which typically resolve within the first week of use (Doron & Snyderman, 2015). However,

caution is warranted in immunocompromised patients, critically ill individuals, and those with severe underlying conditions where bacteremia risk may be elevated.

We came to the conclusion that there is enough proof of safety and effectiveness for consumers and physicians to consider utilizing particular probiotics for certain reasons, such supporting gut function during antibiotic use or to reduce the risk of respiratory tract infections (Sanders *et al.*, 2024). Prebiotics exhibit even better safety profiles, with the primary concern being gastrointestinal intolerance at high doses. Gradual dose escalation typically minimizes these effects while maintaining therapeutic benefits.

#### **2.4 Strain Specificity and Dosage Considerations**

One critical aspect of probiotic therapy is strain specificity. Different strains within the same species may exhibit vastly different properties and clinical effects. For example, while *Lactobacillus rhamnosus* GG demonstrates strong evidence for preventing antibiotic-associated diarrhea, other *L. rhamnosus* strains may not share this property (Hill *et al.*, 2014). Effective probiotic dosages typically range from  $10^8$  to  $10^{11}$  colony-forming units (CFU) per day, though optimal dosing varies by strain and indication. Recent studies highlight the significance of strain selection over number alone by indicating that greater CFU counts do not always correspond with improved effectiveness.

#### **2.5 Emerging Applications**

Recent research has expanded probiotic and prebiotic applications beyond traditional gastrointestinal indications. Studies investigating their roles in mental health through the gut-brain axis show promising preliminary results. The concept of psychobiotics—probiotics that influence brain function and behavior—represents an exciting frontier in microbiome research (Sarkar *et al.*, 2016). Probiotics, prebiotics, and postbiotics help prevent and treat a variety of diseases, according to growing clinical research and data; but, at this time, they are only available as dietary supplements as opposed to medications, which limit the utilization of probiotics in the field of medicine (Ji *et al.*, 2023).

#### **2.6 Methodological Considerations in Research**

Understanding how diet impacts the efficacy of prebiotics and probiotics is limited, despite it being the key determinant of gastrointestinal microbiome composition and function (Walter *et al.*, 2024). This highlights the need for more comprehensive study designs that account for dietary influences on microbiome interventions. Current research trends emphasize the importance of personalized approaches to probiotic and prebiotic therapies. Individual variations in baseline microbiome composition, genetic factors, and lifestyle influences significantly impact treatment responses, suggesting that future therapeutic strategies may require tailored interventions based on individual microbiome profiles.

#### **3.0 CONCLUSION**

The current evidence supports the therapeutic potential of probiotics and prebiotics for specific gastrointestinal conditions, particularly IBD and IBS symptoms management. However, the field is characterized by significant complexities in research methodologies, product formulations, and clinical outcomes. Strain-specific effects, individual variability in response, and the complex nature of gut microbiome interactions necessitate more nuanced approaches to probiotic and prebiotic interventions.

Future research should prioritize strain-specific studies with standardized outcome measures and adequate follow-up periods to assess long-term safety and efficacy. The development of biomarkers for predicting individual responses to probiotics could facilitate personalized treatment approaches, and improve clinical outcomes. Regulatory frameworks should be strengthened to ensure product quality, standardization, and accurate labeling of probiotic and prebiotic products. Healthcare practitioners should exercise caution in recommending these interventions, focusing on evidence-based strain-specific applications rather than general gut health claims. Lastly, collaborative efforts between researchers, clinicians, and regulatory bodies are essential to establish standardized protocols for probiotic and prebiotic research, ultimately advancing the field toward evidence-based therapeutic applications that can reliably benefit patient outcomes.

**Conflict of Interest**

The authors declare that there are no financial or non-financial conflicts of interest.

**REFERENCES**

- Doron, S., & Snyderman, D. R. (2015). Risk and safety of probiotics. *Clinical Microbiology Reviews*, 28(1), 125-181.
- Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018). Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. *Alimentary Pharmacology & Therapeutics*, 48(10), 1044-1060.
- Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K. & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nature Reviews Gastroenterology & Hepatology*, 14(8), 491-502.
- Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, R. B., Flint, H. J., Salminen, S., Calder, P. C. & Sanders, M. E. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews Gastroenterology & Hepatology*, 11(8), 506-514.
- Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023). Probiotics, prebiotics, and postbiotics in health and disease. *MedComm*, 4(6), e420.
- Kerry, R. G., Patra, J. K., Gouda, S., Park, Y., Shin, H. S., & Das, G. (2018). Benefaction of probiotics for human health: A review. *Journal of Food and Drug Analysis*, 26(3), 927-939.
- Martín, R., Miquel, S., Ulmer, J., Kechaou, N., Langella, P., & Bermúdez-Humarán, L. G. (2013). Role of commensal and probiotic bacteria in human health: A focus on inflammatory bowel disease. *Microbial Cell Factories*, 12(1), 1-11.
- McFarland, L. V., Huang, Y., Wang, L., & Malfertheiner, P. (2016). Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for *Helicobacter pylori* eradication and prevention of adverse events. *United European Gastroenterology Journal*, 4(4), 546-561.
- O'Callaghan, A., & van Sinderen, D. (2016). Bifidobacteria and their role as members of the human gut microbiota. *Frontiers in Microbiology*, 7, 925.
- Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A., & Mele, M. C. (2019). What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. *Microorganisms*, 7(1), 14.
- Rodriguez-Herrera, A., Muñoz-Carrillo, J. L., Hernández-Reyes, J., García-Hernández, M. H., Ramos-Gracia, L. G., & Aguilar-Ruiz, S. R. (2024). Impact of probiotics and prebiotics on gut microbiome and hormonal regulation. *Microorganisms*, 6(4), 56.
- Sanders, M. E., Merenstein, D., Merrifield, C. A., & Hutkins, R. (2024). Is there evidence to support probiotic use for healthy people? *Gastroenterology*, 166(5), 991-1005.
- Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. (2016). Psychobiotics and the manipulation of bacteria-gut-brain signals. *Trends in Neurosciences*, 39(11), 763-781.
- Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009). The probiotic preparation, VSL# 3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clinical Gastroenterology and Hepatology*, 7(11), 1202-1209.
- Vandeputte, D., Falony, G., Vieira-Silva, S., Wang, J., Sailer, M., Theis, S., Verbeke, K., & Raes, J. (2017). Prebiotic inulin-type fructans induce specific changes in

- the human gut microbiota. *Gut*, 66(11), 1968-1974.
- Whelan, K., Alexander, M., Gaiani, C., Lunken, G., Holmes, A., Staudacher, H. M., Theis, S. & Marco, M. L. (2024). Design and reporting of prebiotic and probiotic clinical trials in the context of diet and the gut microbiome. *Nature Microbiology*, 9(11): 2785-2794.
- <https://doi.org/10.1038/s41564-024-01831-6>
- Zhang, Y., Chen, L., Hu, M., Kim, J. J., Lin, R., Xu, J., & Wang, Y. (2024). The potential impact of probiotics on human health: An update on their health-promoting properties. *Microorganisms*, 12(2), 234.